YTYi‐Ching Tsai

Yi‐Ching Tsai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi‐Ching Tsai has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Chen-Huan Chen

    Department of Anesthesiology, Taipei Medical University Hospital, Taipei Medical University, No. 252, Wuxing St, Xinyi District, Taipei 110301, Taiwan, ROC; Department of Education and Humanities in Medicine, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei 110301, Taiwan, ROC

    1 shared publication
  • Chern-En Chiang

    General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

    1 shared publication
  • Chi-Jung Huang

    Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    1 shared publication
  • Hao-Min Cheng

    Department of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

    1 shared publication
  • Shih-Hsien Sung

    Cardiovascular Center, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

    1 shared publication
  • Yang-Chin Su

    Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta‐analysis

    by Yi‐Ching Tsai, Yen‐Po Tsao, Chi‐Jung Huang, Yen‐Hsuan Tai, Yang‐Chin Su, Chern‐En Chiang, Shih‐Hsien Sung, Chen‐Huan Chen, Hao‐Min Cheng

    Hypertension‐related death is the leading cause of mortality worldwide, making blood pressure (BP) control an important issue. Salt substitute is a non‐pharmaceutical strategy to improve hypertension control. The goal of this study was to evaluate the effect of salt substitute on BP and cardiovascular disease. The authors searched the Cochrane Library and PubMed databases through March 2022, and assessed the risk‐of‐bias for included studies by the Cochrane risk‐of‐bias tool. Twenty‐three randomized controlled trials with 32073 patients were included in our systematic review. A meta‐analysis with random effects was performed to analyze the effects of salt substitute on systolic and diastolic BP, 24‐h urinary sodium and potassium, and cardiovascular and all‐cause mortality. In the random‐effects model, participants consuming salt substitute showed significant reduction in systolic BP (mean difference (MD) −4.80 mmHg, 95% confidence interval (CI) −6.12 to −3.48, P < 0.0001) and diastolic BP (MD −1.48 mmHg, 95% CI −2.06 to −0.90, P < 0.0001) compared with participants consuming normal salt. In the urine electrolyte analysis, the salt substitute group had significant reduction in 24‐h urine sodium (MD −22.96 mmol/24‐h, P = 0.0001) and significant elevation in 24‐h urine potassium (MD 14.41 mmol/24‐h, P < 0.0001). Of the five studies with mortality outcome data, salt substitute significantly reduced all‐cause mortality (hazard ratio 0.88, P = 0.0003). In conclusion, our analyses showed that salt substitute has a strong effect on lowering BP and reducing all‐cause mortality. By modifying the daily diet with salt substitute, the authors can improve BP control by using this non‐pharmaceutical management.